Filing Flows › Biocryst Pharmaceuticals (BCRX) › Q2 2025
Biocryst Pharmaceuticals (BCRX) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 5, 2025
Biocryst Pharmaceuticals (BCRX) reported revenue of $163M for the second quarter 2025 (Q2 2025), +49% from a year earlier and +12% from the quarter before. Operating margin was 18.2%, net earnings $5.1M (3.1% of revenue).
Biocryst Pharmaceuticals, Q2 2025: revenue $163M (+49% year over year), operating margin 18.2%, net earnings $5.1M, operating cash flow $41.3M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $163M | +12% | +49% |
| Operating profit | $29.8M | +40% | +240% |
| Net earnings | $5.1M | 159× | — |
| Operating cash flow | $41.3M | — | — |
| Free cash flow | $41.1M | — | — |
What changed
Revenue was $163.4M in Q2 2025, up 49% year over year and up 12% from the previous quarter. ORLADEYO was the largest line at 96% of revenue. ORLADEYO added $48.5M year over year (up 45%), 90% of the total change.
Operating profit was $29.8M, a 18.2% margin (up 10.2 points year over year). Of the extra revenue versus a year earlier, 39% reached operating profit, above the 8% margin then. Total costs grew 33% against revenue growth of 49%. The fastest-growing cost line was Cost of revenue (+65%). Net earnings were $5.1M. The effective tax rate was 21.6%.
Operating cash flow was $41.3M, 812% of net earnings. Non-cash charges added back $329K of depreciation and amortization and $21.3M of share-based compensation. Working capital and other items added $14.6M. Capital expenditures of $179K left free cash flow of $41.1M.
Questions
What was Biocryst Pharmaceuticals' revenue in the second quarter 2025?
Biocryst Pharmaceuticals (BCRX) reported revenue of $163M for the second quarter 2025 (Q2 2025), +49% from a year earlier and +12% from the quarter before.
Was Biocryst Pharmaceuticals profitable in the second quarter 2025?
Operating profit was $29.8M (18.2% of revenue) and net earnings $5.1M.